Is there a Bermuda Triangle of drug prices? Do FDA advisers matter? And when should biotech companies throw in the towel?
We cover all that and more this week on "The Readout LOUD," STAT's biotech podcast. We discuss a Senate hearing that put major pharma CEOs in the same room with the middlemen they love to blame for rising drug prices, with mixed results. We also explain what is a massive week for Sarepta Therapeutics, the FDA, and the future of gene therapies for rare diseases, plus the latest news in the life sciences.
Listen Now
Subscribe to the podcast to never miss an episode
Visit the archive to see past episodes
Sign up for the Color Code newsletter to get alerts about new episodes of our podcast on racial health inequities, which drop every other week this spring.
No comments